Publications by authors named "Richard P Beckmann"

Claim this Profile
A
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Wayne D Blosser, Jack A Dempsey, Ann M McNulty, Xi Rao, Philip J Ebert, Richard P Beckmann

Oncotarget· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Richard P Beckmann

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Caitlin D Lowery, Michele Dowless, Matthew Renschler, Wayne Blosser, Alle B VanWye, Richard P Beckmann

Clin Cancer Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
David A Schaer, Richard P Beckmann, Jack A Dempsey, Lysiane Huber, Amelie Forest

Cell Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Xueqian Gong, Lacey M Litchfield, Yue Webster, Li-Chun Chio, Swee Seong Wong, Richard P Beckmann

Cancer Cell· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.
Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, Carmen Baquero, Beatriz Alvarez, Richard P Beckmann

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Caitlin D Lowery, Alle B VanWye, Michele Dowless, Wayne Blosser, Beverly L Falcon, Richard P Beckmann

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair.
Aimee Bence Lin, Samuel C McNeely, Richard P Beckmann

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Amita Patnaik, Lee S Rosen, Sara M Tolaney, Anthony W Tolcher, Jonathan W Goldman, Richard P Beckmann

Cancer Discov· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Sonya C Tate, Teresa F Burke, Daisy Hartman, Palaniappan Kulanthaivel, Richard P Beckmann

Br J Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.
Vipin Yadav, Shih-Hsun Chen, Yong Gong Yue, Sean Buchanan, Richard P Beckmann

Pharmacol Ther· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Vipin Yadav, Teresa F Burke, Lysiane Huber, Robert D Van Horn, Youyan Zhang, Richard P Beckmann

Mol Cancer Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Sonya C Tate, Shufen Cai, Rose T Ajamie, Teresa Burke, Richard P Beckmann

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.
Chafiq Hamdouchi, Heather Keyser, Elizabeth Collins, Carlos Jaramillo, Jose Eugenio De Diego, Richard P Beckmann

Mol Cancer Ther· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis